Taysha Gene Therapies Income from Continuous Operations 2020-2024 | TSHA

Taysha Gene Therapies income from continuous operations from 2020 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change

Taysha Gene Therapies Income from Continuous Operations 2020-2024 | TSHA

Taysha Gene Therapies income from continuous operations from 2020 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$19B
Dr Reddy's Laboratories (RDY)$12B
BridgeBio Pharma (BBIO)$4.3B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.1B
Supernus Pharmaceuticals (SUPN)$2B
Personalis (PSNL)$261M
Assembly Biosciences (ASMB)$98M
Sol-Gel Technologies (SLGL)$12M
Evoke Pharma (EVOK)$7M
Teligent (TLGT)$0M